{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:33:02Z","timestamp":1787002382426,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2009,6,30]],"date-time":"2009-06-30T00:00:00Z","timestamp":1246320000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cell Res"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1038\/cr.2009.80","type":"journal-article","created":{"date-parts":[[2009,6,30]],"date-time":"2009-06-30T06:39:00Z","timestamp":1246343940000},"page":"1079-1089","source":"Crossref","is-referenced-by-count":28,"title":["Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of cIAP-1 and cIAP-2 through inhibition of Jak2\/Stat3"],"prefix":"10.1038","volume":"19","author":[{"given":"Paola","family":"Lanuti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Bertagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pierdomenico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Bascelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Santavenere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lapo","family":"Alinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvano","family":"Capitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Miscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Marchisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,6,30]]},"reference":[{"key":"BFcr200980_CR1","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S0140-6736(04)17089-X","volume":"364","author":"T Eden","year":"2004","unstructured":"Eden T, Pui CH, Schrappe M, Tognoni G, Masera G . All children have a right to full access to treatment for cancer. Lancet 2004; 364:1121\u20131122.","journal-title":"Lancet"},{"key":"BFcr200980_CR2","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1038\/sj.leu.2403946","volume":"19","author":"SH Kaufman","year":"2005","unstructured":"Kaufman SH, Steensma DP . On the TRAIL of a new therapy for leukemia. Leukemia 2005; 19:2195\u20132202.","journal-title":"Leukemia"},{"key":"BFcr200980_CR3","first-page":"3526","volume":"21","author":"A Younes","year":"2003","unstructured":"Younes A, Kadin ME . Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Invest 2003; 21:3526\u20133534.","journal-title":"J Clin Invest"},{"key":"BFcr200980_CR4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.coph.2004.02.006","volume":"4","author":"SK Kelley","year":"2004","unstructured":"Kelley SK, Ashkenazi A . Death to the bad guys: targeting death receptors in cancer with Apo2L\/TRAIL. Curr Opin Pharmacol 2004; 4:333\u2013339.","journal-title":"Curr Opin Pharmacol"},{"key":"BFcr200980_CR5","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/j.ejca.2006.03.018","volume":"42","author":"EW Duiker","year":"2006","unstructured":"Duiker EW, Mom CH, de Jong S, et al. The clinical trail of TRAIL. Eur J Cancer 2006; 42:2233\u20132240.","journal-title":"Eur J Cancer"},{"key":"BFcr200980_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0378-4274(02)00422-8","volume":"139","author":"M MacFarlane","year":"2003","unstructured":"MacFarlane M . TRAIL-induced signalling and apoptosis. Toxicol Lett 2003; 139:89\u201397.","journal-title":"Toxicol Lett"},{"key":"BFcr200980_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nrd772","volume":"1","author":"RW Johnstone","year":"2002","unstructured":"Johnstone RW . Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1:287\u2013299.","journal-title":"Nat Rev Drug Discov"},{"key":"BFcr200980_CR8","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.1038\/sj.onc.1208585","volume":"24","author":"TR Singh","year":"2005","unstructured":"Singh TR, Shankar S, Srivastava RK . HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 2005; 24:4609\u20134623.","journal-title":"Oncogene"},{"key":"BFcr200980_CR9","first-page":"893","volume":"1","author":"L Burdelya","year":"2002","unstructured":"Burdelya L, Catlett-Falcone R, Levitzki A, et al. Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Mol Cancer Ther 2002; 1:893\u2013899.","journal-title":"Mol Cancer Ther"},{"key":"BFcr200980_CR10","doi-asserted-by":"publisher","first-page":"8404","DOI":"10.1038\/sj.onc.1206047","volume":"21","author":"SO Rahaman","year":"2002","unstructured":"Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ . Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 2002; 21:8404\u20138413.","journal-title":"Oncogene"},{"key":"BFcr200980_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0304-3835(03)00482-8","volume":"201","author":"T Toyonaga","year":"2003","unstructured":"Toyonaga T, Nakano K, Nagano M, et al. Blockade of constitutively activated Janus kinase\/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. Cancer Lett 2003; 201:107\u2013116.","journal-title":"Cancer Lett"},{"key":"BFcr200980_CR12","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.4049\/jimmunol.162.7.3897","volume":"162","author":"LH Wang","year":"1999","unstructured":"Wang LH, Kirken RA, Erwin RA, Yu CR, Farrar WL . JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response. J Immunol 1999; 162:3897\u20133904.","journal-title":"J Immunol"},{"key":"BFcr200980_CR13","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.bcp.2006.07.008","volume":"72","author":"JH Yu","year":"2006","unstructured":"Yu JH, Kim KH, Kim H . Suppression of IL-1\u03b2 expression by the Jak2 inhibitor AG-490 in cerulean-stimulated pancreatic acinar cells. Biochem Pharmacol 2006; 72:1555\u20131562.","journal-title":"Biochem Pharmacol"},{"key":"BFcr200980_CR14","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1046\/j.1365-2141.2000.02127.x","volume":"109","author":"J De Vos","year":"2000","unstructured":"De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B . JAK2 tyrosine kinase inhibitor tyrphostin AG-490 down regulates the mitogen activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol 2000; 109:823\u2013828.","journal-title":"Br J Haematol"},{"key":"BFcr200980_CR15","doi-asserted-by":"publisher","first-page":"13897","DOI":"10.1073\/pnas.94.25.13897","volume":"94","author":"S Takemoto","year":"1997","unstructured":"Takemoto S, Mulloy JC, Cereseto A, et al. Proliferation of adult T cell leukemia\/lymphoma cells is associated with the constitutive activation of JAK\/STAT proteins. Proc Natl Acad Sci USA 1997; 94:13897\u201313902.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcr200980_CR16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1586\/1744666X.1.3.307","volume":"1","author":"SM Stepkowski","year":"2005","unstructured":"Stepkowski SM and Kirken RA . Unique advantages of Janus Kinase 3 as a target for selective and nontoxic immunosuppression. Expert Rev Clin Immunol 2005; 1:307\u2013310.","journal-title":"Expert Rev Clin Immunol"},{"key":"BFcr200980_CR17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/379645a0","volume":"379","author":"N Meydan","year":"1996","unstructured":"Meydan N, Grunberger T, Dadi H, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996; 379:645\u2013648.","journal-title":"Nature"},{"key":"BFcr200980_CR18","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/jlb.65.6.891","volume":"65","author":"RA Kirken","year":"1999","unstructured":"Kirken RA, Erwin RA, Taub D, et al. Tyrphostin AG-490 inhibits cytokine-mediated JAK3\/STAT5a\/b signal transduction and cellular proliferation of antigen-activated human T cells. J Leukoc Biol 1999; 65:891\u2013899.","journal-title":"J Leukoc Biol"},{"key":"BFcr200980_CR19","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s000180050392","volume":"19","author":"TC Yeh","year":"1999","unstructured":"Yeh TC, Pellegrini S . The Janus Kinase family of protein tyrosine kinase and their role in signalling. Cell Mol Life Sci 1999; 19:1523\u20131534.","journal-title":"Cell Mol Life Sci"},{"key":"BFcr200980_CR20","doi-asserted-by":"publisher","first-page":"4052","DOI":"10.1128\/MCB.01591-05","volume":"26","author":"AM Mazurkiewicz-Munoz","year":"2006","unstructured":"Mazurkiewicz-Munoz AM, Argetsinger LS, Kouadio JL, et al. Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 that is stimulated by growth hormone and epidermal growth factor. Mol Cell Biol 2006; 26:4052\u20134062.","journal-title":"Mol Cell Biol"},{"key":"BFcr200980_CR21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/sj.cdd.4400656","volume":"7","author":"A Stephanou","year":"2000","unstructured":"Stephanou A, Brar BK, Knight RA, Latchman DS . Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ 2000; 7:329\u2013330.","journal-title":"Cell Death Differ"},{"key":"BFcr200980_CR22","first-page":"5137","volume":"61","author":"S Alas","year":"2001","unstructured":"Alas S, Bonavida B . Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine\/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001; 61:5137\u20135144.","journal-title":"Cancer Res"},{"key":"BFcr200980_CR23","first-page":"316","volume":"9","author":"S Alas","year":"2003","unstructured":"Alas S, Bonavida B . Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 2003; 9:316\u2013326.","journal-title":"Clin Cancer Res"},{"key":"BFcr200980_CR24","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1182\/blood-2002-05-1505","volume":"101","author":"T Hasegawa","year":"2003","unstructured":"Hasegawa T, Suzuki K, Sakamoto C, et al. Expression of the inhibitor of aoptosis (IAP) family members in human neutrophils: up-regulation of cIAP-2 by granulocyte colony-stimulating factor and overexpression of cIAP-2 in chronic neutrophilic leukaemia. Blood 2003; 101:1164\u20131171.","journal-title":"Blood"},{"key":"BFcr200980_CR25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.molmed.2006.06.002","volume":"12","author":"E Bremer","year":"2006","unstructured":"Bremer E, van Dam G, Kroesen BJ, de Leij L, Helfrich W . Target induction of apoptosis for cancer therapy: current progress and prospects. Trends Mol Med 2006; 12:382\u2013393.","journal-title":"Trends Mol Med"},{"key":"BFcr200980_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1535-6108(03)00332-5","volume":"5","author":"AD Schimmer","year":"2004","unstructured":"Schimmer AD, Welsh K, Pinilla C, et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004; 5: 25\u201335.","journal-title":"Cancer Cell"},{"key":"BFcr200980_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1101\/gad.13.3.239","volume":"13","author":"QL Deveraux","year":"1999","unstructured":"Deveraux QL, Reed JC . IAP family proteins-suppressors of apoptosis. Gen Dev 1999; 13:239\u2013252.","journal-title":"Gen Dev"},{"key":"BFcr200980_CR28","doi-asserted-by":"publisher","first-page":"10057","DOI":"10.1073\/pnas.94.19.10057","volume":"94","author":"ZL Chu","year":"1997","unstructured":"Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW . Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-\u03baB control. Proc Natl Acad Sci USA 1997; 94:10057\u201310062.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcr200980_CR29","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1073\/pnas.0409894102","volume":"102","author":"H Song","year":"2005","unstructured":"Song H, Wang R, Wang S, Lin J . A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 2005; 102:4700\u20134705.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcr200980_CR30","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.bmcl.2007.10.031","volume":"18","author":"D Bhasin","year":"2008","unstructured":"Bhasin D, Cisek K, Pandharkar T, et al. Design, synthesis, and studies of small molecule STAT3 inhibitors. Bioorg Med Chem Lett 2008; 18:391\u2013395.","journal-title":"Bioorg Med Chem Lett"},{"key":"BFcr200980_CR31","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1471-2407-7-78","volume":"7","author":"CL Chen","year":"2007","unstructured":"Chen CL, Loy A, Cen L, et al. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer 2007; 7:78\u201390.","journal-title":"BMC Cancer"},{"key":"BFcr200980_CR32","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1016\/j.febslet.2005.09.009","volume":"579","author":"E Mori","year":"2005","unstructured":"Mori E, Thomas M, Motoki K, Kataika S . Distinct function of monoclonal antibody to TRAIL-R2 as potentiator or inhibitor of the ligand TRAIL-induced apoptosis. FEBS Lett 2005; 579:5379\u20135384.","journal-title":"FEBS Lett"},{"key":"BFcr200980_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/sj.cdd.4401331","volume":"11","author":"E Mori","year":"2004","unstructured":"Mori E, Thomas M, Motoki K, et al. Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ 2004; 11:203\u2013207.","journal-title":"Cell Death Differ"},{"key":"BFcr200980_CR34","doi-asserted-by":"publisher","first-page":"21337","DOI":"10.1074\/jbc.M608810200","volume":"282","author":"N Mazurek","year":"2007","unstructured":"Mazurek N, Sun YJ, Liu KF, et al. Phosphorylated galectin-3 mediates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) signaling by regulating PTEN in human breast carcinoma cells. J Biol Chem 2007; 282:21337\u201321348.","journal-title":"J Biol Chem"},{"key":"BFcr200980_CR35","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1056\/NEJM199808273390907","volume":"339","author":"CH Pui","year":"1998","unstructured":"Pui CH, Evans WE . Acute lymphoblastic leukemia. N Engl J Med 1998; 339:605\u2013615.","journal-title":"N Engl J Med"},{"key":"BFcr200980_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11864-000-0012-2","volume":"1","author":"MR Litzow","year":"2000","unstructured":"Litzow MR . Acute lymphoblastic leukemia in adults. Curr Treat Options Oncol 2000; 1:19\u201329.","journal-title":"Curr Treat Options Oncol"},{"key":"BFcr200980_CR37","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.cellsig.2005.12.004","volume":"18","author":"P Wang","year":"2006","unstructured":"Wang P, Song JH, Song DK, Zhang J, Hao C . Role of death receptor and mitochondrial pathways in conventional chemotherapy drug induction of apoptosis. Cell Signal 2006; 18:1528\u20131535.","journal-title":"Cell Signal"},{"key":"BFcr200980_CR38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.surg.2005.03.001","volume":"138","author":"T Mori","year":"2005","unstructured":"Mori T, Doi R, Toyoda E, et al. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer. Surgery 2005; 138:71\u201377.","journal-title":"Surgery"},{"key":"BFcr200980_CR39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1196\/annals.1378.023","volume":"1090","author":"O Meurette","year":"2006","unstructured":"Meurette O, Fontaine A, Rebillard A, et al. Cytotoxicity of TRAIL\/anticancer drug combinations in human normal cells. Ann N Y Acad Sci 2006; 1090:209\u2013216.","journal-title":"Ann N Y Acad Sci"},{"key":"BFcr200980_CR40","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/hep.20807","volume":"42","author":"TM Ganten","year":"2005","unstructured":"Ganten TM, Koschny R, Haas TL, et al. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 2005; 42:588\u2013597.","journal-title":"Hepatology"},{"key":"BFcr200980_CR41","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1182\/blood.V97.9.2596","volume":"97","author":"R Di Pietro","year":"2001","unstructured":"Di Pietro R, Secchiero P, Rana R, et al. Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1. Blood 2001; 97:2596\u20132603.","journal-title":"Blood"},{"key":"BFcr200980_CR42","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/j.1365-2141.2005.05690.x","volume":"130","author":"AO de Graaf","year":"2005","unstructured":"de Graaf AO, van Krieken JH, Tonnissen E, et al. Expression of C-IAP1, C-IAP2 and SURVIVIN discriminates different types of lymphoid malignancies. Br J Haematol 2005; 130:852\u2013859.","journal-title":"Br J Haematol"},{"key":"BFcr200980_CR43","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1038\/sj.onc.1203486","volume":"19","author":"TS Lin","year":"2000","unstructured":"Lin TS, Mahajan S, Frank DA . STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 2000; 19:2496\u20132504.","journal-title":"Oncogene"},{"key":"BFcr200980_CR44","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.bbrc.2005.12.014","volume":"340","author":"J Rajasingh","year":"2006","unstructured":"Rajasingh J, Raikwar HP, Muthian G, Johnson C, Bright JJ . Curcumin induces growth-arrest and apoptosis in association with the inhibition of costitutively active JAK-STAT pathway in T cell leukemia. Bioc Biophis Res Comm 2006; 340:359\u2013368.","journal-title":"Bioc Biophis Res Comm"},{"key":"BFcr200980_CR45","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1742-4690-3-22","volume":"3","author":"M Tomita","year":"2006","unstructured":"Tomita M, Kawakami H, Uchihara JN, et al. Inhibition of constitutively active Jak-Stat pathway suppresses cell growth of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. Retrovirology 2006; 3:22\u201332.","journal-title":"Retrovirology"},{"key":"BFcr200980_CR46","first-page":"595","volume":"21","author":"R Moriai","year":"2001","unstructured":"Moriai R, Asanuma K, Kobayashi D, et al. Quantitative analysis of the anti-apoptotic gene surviving expression in malignant haematopoietic cells. Anticancer Res 2001; 21:595\u2013600.","journal-title":"Anticancer Res"},{"key":"BFcr200980_CR47","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.leukres.2003.10.013","volume":"28","author":"Y Nakagawa","year":"2004","unstructured":"Nakagawa Y, Yamaguchi S, Hasegawa M, et al. Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukaemia and chronic lymphocytic leukemia. Leukemia Res 2004; 28:487\u2013494.","journal-title":"Leukemia Res"},{"key":"BFcr200980_CR48","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1046\/j.1365-2141.2001.02902.x","volume":"114","author":"S Kamihira","year":"2001","unstructured":"Kamihira S, Yamada Y, Hirakata Y, et al. Aberrant expression of caspase cascade regulatory genes in adult T-cell leukaemia: survivin is an important determinant for prognosis. Br J Haematol 2001; 114:63\u201369.","journal-title":"Br J Haematol"},{"key":"BFcr200980_CR49","first-page":"127","volume":"28","author":"P Mirandola","year":"2006","unstructured":"Mirandola P, Sponzilli I, Gobbi G, et al. Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins. Int J Oncol 2006; 28:127\u2013133.","journal-title":"Int J Oncol"},{"key":"BFcr200980_CR50","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1182\/blood-2002-06-1770","volume":"101","author":"K Uno","year":"2003","unstructured":"Uno K, Inukai T, Kayagaki N, et al. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome positive leukaemia cells. Blood 2003; 101:3658\u20133667.","journal-title":"Blood"},{"key":"BFcr200980_CR51","doi-asserted-by":"publisher","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","volume":"271","author":"RM Pitti","year":"1996","unstructured":"Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A . Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271:12687\u201312690.","journal-title":"J Biol Chem"},{"key":"BFcr200980_CR52","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1136\/ijgc-00009577-200507000-00013","volume":"15","author":"HX Chen","year":"2005","unstructured":"Chen HX, Liu YJ, Zhou XD, Lou RY . Expression of cellular FLICE\/caspase-8 inhibitory protein is associated with malignant potential in endometrial carcinoma. Int J Gynecol Cancer 2005; 15:663\u2013670.","journal-title":"Int J Gynecol Cancer"},{"key":"BFcr200980_CR53","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.cellsig.2003.09.013","volume":"16","author":"V Bertagnolo","year":"2004","unstructured":"Bertagnolo V, Brugnoli F, Marchisio M, Celeghini C, Carini C, Capitani S . Association of PI 3-K with tyrosine phosphorylated Vav is essential for its activity in neutrophil-like maturation of myeloid cells. Cell Signal 2004; 16:423\u2013433.","journal-title":"Cell Signal"}],"container-title":["Cell Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/cr200980.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cr200980","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cr200980.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T16:58:03Z","timestamp":1685033883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cr200980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,30]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["BFcr200980"],"URL":"https:\/\/doi.org\/10.1038\/cr.2009.80","relation":{},"ISSN":["1001-0602","1748-7838"],"issn-type":[{"value":"1001-0602","type":"print"},{"value":"1748-7838","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,30]]}}}